Can bone marrow stem cells calm lupus kidney flares?

NCT ID NCT03673748

Recruiting now Disease control Sponsor: Red de Terapia Celular Source: ClinicalTrials.gov ↗

First seen Aug 18, 2026 · Last updated Aug 19, 2026 · Updated 1 time

Summary

This trial tests whether a single intravenous dose of mesenchymal stem cells, derived from bone marrow, can safely help adults with active lupus nephritis achieve a complete or partial kidney response. Participants receive either the stem cells or a placebo (saline) in a double-blind design. The study measures how many people reach improved kidney function and reduced protein in the urine, and whether steroid doses can be lowered.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Mesenchymal stem cells (MSC) from bone marrow, given by intravenous injection
What this could lead to: If successful, this could offer a new way to control lupus nephritis and reduce the need for high-dose steroids.
What could go wrong: This is an early-phase, small trial, so results may not apply broadly. Risks include infusion reactions and unknown long-term effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUPUS ERYTHEMATOSUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune disease lupus erythematosus lupus nephritis systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUPUS ERYTHEMATOSUS LUPUS NEPHRITIS

Contacts and locations

Locations

University Hospital Río Hortega
RECRUITING

Valladolid, Valladolid, 47012, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.